AltheRx Pharmaceuticals
Glenmoore
About AltheRx Pharmaceuticals
AltheRx Pharmaceuticals is a privately held, clinical development company focused on advancing best-in-class compounds with high promise in large unmet markets. The Company is focused on clinical development and optimizing commercialization through partnerships. The AltheRx name is a derivative of the name of the Greek goddess of healing, Althea. The Company’s lead product, Solabegron, is a highly differentiated novel compound being investigated for OAB and IBS, conditions that affect the quality of life for more than 90 million Americans ΓêÆ a number that will grow significantly as the population ages. Solabegron was discovered and first developed by GlaxoSmithKline and acquired by AltheRx in March 2011. The company’s co-founders have decades of leadership experience in the pharmaceutical and biotechnology industries. AltheRx was formed in 2010.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $15.0M
- Funding stage: M&A
- Last round: Series Unknown (May 2013)
- Website: altherx.com
Industries & Categories
Biotechnology, Health Care, Medical Device
Canonical: https://fsome.com/organization/altherx-pharmaceuticals-2437583 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.